| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 15 | 2017 | 475 | 2.360 |
Why?
|
| Coronary Artery Bypass | 10 | 2017 | 103 | 1.970 |
Why?
|
| Aortic Valve | 4 | 2018 | 49 | 1.900 |
Why?
|
| Heart Valve Prosthesis | 4 | 2018 | 55 | 1.810 |
Why?
|
| Bioprosthesis | 4 | 2018 | 58 | 1.800 |
Why?
|
| Heart Valve Prosthesis Implantation | 5 | 2018 | 39 | 1.440 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2018 | 24 | 1.340 |
Why?
|
| Thrombolytic Therapy | 5 | 2013 | 63 | 1.150 |
Why?
|
| Coronary Artery Disease | 10 | 2020 | 401 | 1.090 |
Why?
|
| Myocardial Reperfusion | 4 | 2012 | 10 | 1.080 |
Why?
|
| Stents | 6 | 2018 | 177 | 1.030 |
Why?
|
| Ventricular Dysfunction, Left | 10 | 2017 | 170 | 1.000 |
Why?
|
| Bone Marrow Transplantation | 10 | 2017 | 63 | 0.990 |
Why?
|
| Risk Assessment | 8 | 2020 | 1429 | 0.920 |
Why?
|
| Vascular Surgical Procedures | 2 | 2017 | 88 | 0.860 |
Why?
|
| Treatment Outcome | 21 | 2020 | 3306 | 0.840 |
Why?
|
| Aortic Valve Stenosis | 2 | 2020 | 30 | 0.800 |
Why?
|
| Time Factors | 13 | 2020 | 2150 | 0.750 |
Why?
|
| Disease Management | 5 | 2015 | 126 | 0.730 |
Why?
|
| Electrocardiography | 7 | 2015 | 605 | 0.720 |
Why?
|
| Cardiology | 8 | 2020 | 99 | 0.710 |
Why?
|
| Echocardiography | 3 | 2020 | 159 | 0.710 |
Why?
|
| Coronary Angiography | 6 | 2020 | 153 | 0.670 |
Why?
|
| Humans | 52 | 2020 | 32113 | 0.660 |
Why?
|
| Prosthesis Failure | 1 | 2018 | 45 | 0.640 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 99 | 0.630 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 103 | 0.630 |
Why?
|
| Tricuspid Valve | 1 | 2017 | 5 | 0.610 |
Why?
|
| Acute Coronary Syndrome | 1 | 2020 | 196 | 0.600 |
Why?
|
| Foramen Ovale, Patent | 1 | 2017 | 8 | 0.600 |
Why?
|
| Catheterization, Peripheral | 1 | 2017 | 29 | 0.590 |
Why?
|
| Femoral Artery | 1 | 2017 | 50 | 0.590 |
Why?
|
| Thrombosis | 1 | 2017 | 73 | 0.580 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 57 | 0.570 |
Why?
|
| Mitral Valve Stenosis | 1 | 2016 | 8 | 0.560 |
Why?
|
| Aged | 21 | 2020 | 10314 | 0.530 |
Why?
|
| Retrospective Studies | 11 | 2018 | 3510 | 0.530 |
Why?
|
| Prosthesis Design | 4 | 2018 | 97 | 0.500 |
Why?
|
| Risk Factors | 9 | 2020 | 3880 | 0.490 |
Why?
|
| Heart-Assist Devices | 4 | 2011 | 25 | 0.480 |
Why?
|
| Female | 26 | 2020 | 20014 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 408 | 0.430 |
Why?
|
| Radial Artery | 1 | 2012 | 16 | 0.430 |
Why?
|
| Male | 26 | 2020 | 19216 | 0.420 |
Why?
|
| Specialization | 1 | 2012 | 31 | 0.420 |
Why?
|
| Middle Aged | 22 | 2020 | 11839 | 0.420 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 3990 | 0.400 |
Why?
|
| Evidence-Based Medicine | 7 | 2015 | 218 | 0.400 |
Why?
|
| Heart Transplantation | 2 | 2011 | 27 | 0.390 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2011 | 73 | 0.390 |
Why?
|
| American Heart Association | 5 | 2016 | 87 | 0.390 |
Why?
|
| Life Support Systems | 1 | 2010 | 4 | 0.370 |
Why?
|
| Coronary Circulation | 2 | 2012 | 43 | 0.360 |
Why?
|
| Coronary Disease | 2 | 2009 | 211 | 0.350 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2009 | 3 | 0.340 |
Why?
|
| Myocardial Ischemia | 5 | 2015 | 107 | 0.340 |
Why?
|
| Hemodynamics | 4 | 2018 | 155 | 0.340 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2009 | 17 | 0.340 |
Why?
|
| Operating Rooms | 1 | 2009 | 35 | 0.320 |
Why?
|
| Hypertension, Pulmonary | 3 | 2014 | 24 | 0.320 |
Why?
|
| Adult | 15 | 2020 | 9380 | 0.310 |
Why?
|
| Coronary Stenosis | 1 | 2007 | 30 | 0.300 |
Why?
|
| Ventricular Function, Left | 7 | 2020 | 245 | 0.300 |
Why?
|
| Sirolimus | 1 | 2007 | 33 | 0.300 |
Why?
|
| Recovery of Function | 3 | 2018 | 199 | 0.290 |
Why?
|
| Shock, Cardiogenic | 1 | 2006 | 10 | 0.280 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 104 | 0.280 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 4 | 2012 | 12 | 0.270 |
Why?
|
| Medication Therapy Management | 4 | 2012 | 12 | 0.270 |
Why?
|
| Coronary Vasospasm | 1 | 2005 | 4 | 0.260 |
Why?
|
| Bone Marrow Cells | 3 | 2016 | 123 | 0.260 |
Why?
|
| Vasoconstriction | 1 | 2005 | 43 | 0.260 |
Why?
|
| United States | 8 | 2016 | 3976 | 0.250 |
Why?
|
| Heart Failure | 4 | 2018 | 639 | 0.240 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2014 | 7 | 0.240 |
Why?
|
| Clinical Protocols | 3 | 2012 | 97 | 0.240 |
Why?
|
| Patient Selection | 4 | 2012 | 276 | 0.240 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2013 | 83 | 0.230 |
Why?
|
| Combined Modality Therapy | 6 | 2013 | 560 | 0.220 |
Why?
|
| Emergency Medical Services | 4 | 2012 | 178 | 0.220 |
Why?
|
| Saphenous Vein | 2 | 2017 | 20 | 0.220 |
Why?
|
| Stroke Volume | 6 | 2020 | 348 | 0.200 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 2265 | 0.200 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2011 | 42 | 0.180 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 1128 | 0.180 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 881 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2010 | 56 | 0.170 |
Why?
|
| Double-Blind Method | 7 | 2017 | 525 | 0.170 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 23 | 0.170 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 158 | 0.160 |
Why?
|
| Lung Injury | 1 | 2019 | 68 | 0.160 |
Why?
|
| Antigens, CD34 | 2 | 2016 | 57 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 172 | 0.150 |
Why?
|
| Endothelial Cells | 1 | 2019 | 189 | 0.150 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2017 | 24 | 0.150 |
Why?
|
| Septal Occluder Device | 1 | 2017 | 5 | 0.150 |
Why?
|
| Punctures | 1 | 2017 | 33 | 0.150 |
Why?
|
| Regeneration | 1 | 2019 | 170 | 0.150 |
Why?
|
| Lung | 1 | 2019 | 249 | 0.150 |
Why?
|
| Cohort Studies | 5 | 2016 | 1817 | 0.140 |
Why?
|
| Incidence | 1 | 2020 | 1199 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2017 | 188 | 0.140 |
Why?
|
| Length of Stay | 1 | 2017 | 314 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2017 | 355 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 510 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2015 | 41 | 0.130 |
Why?
|
| Exercise Tolerance | 1 | 2016 | 125 | 0.130 |
Why?
|
| North Carolina | 1 | 2020 | 1538 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2016 | 164 | 0.130 |
Why?
|
| Thrombectomy | 1 | 2015 | 74 | 0.120 |
Why?
|
| Vascular Resistance | 1 | 2014 | 31 | 0.120 |
Why?
|
| Colony-Forming Units Assay | 1 | 2014 | 19 | 0.120 |
Why?
|
| Calcium Channel Blockers | 1 | 2014 | 48 | 0.120 |
Why?
|
| Vasodilation | 1 | 2014 | 94 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2013 | 24 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 43 | 0.110 |
Why?
|
| Terminology as Topic | 1 | 2013 | 65 | 0.110 |
Why?
|
| Stem Cells | 1 | 2015 | 313 | 0.110 |
Why?
|
| Fluoroscopy | 1 | 2012 | 40 | 0.110 |
Why?
|
| Neuregulin-1 | 1 | 2011 | 1 | 0.100 |
Why?
|
| Intraoperative Care | 2 | 2009 | 48 | 0.100 |
Why?
|
| Transplantation, Autologous | 4 | 2012 | 80 | 0.090 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2010 | 4 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2010 | 25 | 0.090 |
Why?
|
| Catheterization | 1 | 2010 | 58 | 0.090 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2010 | 56 | 0.090 |
Why?
|
| Young Adult | 1 | 2017 | 2665 | 0.090 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2010 | 16 | 0.090 |
Why?
|
| Interinstitutional Relations | 1 | 2010 | 12 | 0.090 |
Why?
|
| Equipment Design | 1 | 2010 | 171 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2011 | 116 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2011 | 238 | 0.080 |
Why?
|
| Venous Pressure | 1 | 2009 | 9 | 0.080 |
Why?
|
| Radiography, Interventional | 1 | 2009 | 37 | 0.080 |
Why?
|
| Vascular Patency | 1 | 2009 | 69 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 130 | 0.080 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2008 | 11 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 159 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 876 | 0.080 |
Why?
|
| Pipecolic Acids | 1 | 2008 | 6 | 0.080 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 30 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 1328 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 209 | 0.080 |
Why?
|
| Heparin | 1 | 2008 | 73 | 0.080 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 70 | 0.080 |
Why?
|
| Research Design | 4 | 2010 | 315 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 582 | 0.070 |
Why?
|
| Algorithms | 1 | 2009 | 495 | 0.070 |
Why?
|
| Heart Valve Diseases | 1 | 2006 | 27 | 0.070 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 41 | 0.070 |
Why?
|
| Endothelins | 1 | 2005 | 4 | 0.070 |
Why?
|
| CD40 Ligand | 1 | 2005 | 12 | 0.070 |
Why?
|
| E-Selectin | 1 | 2005 | 20 | 0.070 |
Why?
|
| Blood Proteins | 1 | 2005 | 19 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2016 | 2282 | 0.070 |
Why?
|
| Serotonin | 1 | 2005 | 38 | 0.070 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2006 | 25 | 0.060 |
Why?
|
| Atrial Fibrillation | 1 | 2008 | 322 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 297 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2007 | 1269 | 0.060 |
Why?
|
| Prognosis | 2 | 2020 | 1497 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2012 | 22 | 0.050 |
Why?
|
| Interdisciplinary Communication | 2 | 2011 | 58 | 0.050 |
Why?
|
| Consensus | 1 | 2020 | 85 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 128 | 0.040 |
Why?
|
| Respiratory Distress Syndrome, Adult | 1 | 2019 | 52 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 46 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 483 | 0.040 |
Why?
|
| Prevalence | 2 | 2013 | 988 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 264 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 16 | 0.040 |
Why?
|
| Microcirculation | 1 | 2017 | 65 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2010 | 548 | 0.040 |
Why?
|
| Sepsis | 1 | 2019 | 161 | 0.040 |
Why?
|
| Organ Size | 1 | 2017 | 218 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2017 | 135 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 11 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 472 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2015 | 50 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 238 | 0.030 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 1 | 2014 | 2 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2014 | 70 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2014 | 111 | 0.030 |
Why?
|
| Dehydration | 1 | 2013 | 8 | 0.030 |
Why?
|
| Acute Disease | 1 | 2014 | 253 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 301 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 2484 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 633 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2016 | 923 | 0.030 |
Why?
|
| Coronary Restenosis | 1 | 2012 | 13 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 2012 | 22 | 0.030 |
Why?
|
| Smoking | 1 | 2016 | 528 | 0.030 |
Why?
|
| Injections | 1 | 2012 | 64 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 517 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2013 | 122 | 0.020 |
Why?
|
| Tennessee | 1 | 2011 | 102 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 154 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 112 | 0.020 |
Why?
|
| Graft Survival | 1 | 2012 | 313 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2010 | 15 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 53 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2010 | 23 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 11 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2010 | 14 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 14 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2011 | 129 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 105 | 0.020 |
Why?
|
| Ventricular Remodeling | 1 | 2010 | 58 | 0.020 |
Why?
|
| Program Development | 1 | 2010 | 97 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 81 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2009 | 3 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 449 | 0.020 |
Why?
|
| Pulmonary Veins | 1 | 2009 | 10 | 0.020 |
Why?
|
| Hypertension | 1 | 2016 | 960 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 24 | 0.020 |
Why?
|
| Myocardium | 1 | 2010 | 186 | 0.020 |
Why?
|
| Diastole | 1 | 2009 | 96 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 406 | 0.020 |
Why?
|
| Platelet Count | 1 | 2008 | 23 | 0.020 |
Why?
|
| Obesity | 1 | 2016 | 1176 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 294 | 0.020 |
Why?
|
| Animals | 1 | 2019 | 7542 | 0.020 |
Why?
|
| Sternum | 1 | 2006 | 14 | 0.020 |
Why?
|
| Angiography | 1 | 2006 | 80 | 0.020 |
Why?
|
| Survival Rate | 1 | 2006 | 877 | 0.010 |
Why?
|